Indeed, the use of specific PKC antisense oligonucleotides to reduce PKC levels is an attractive potential treatment of neurodegenerative diseases, as antisense strategies have been shown to successfully reduce LRRK2 protein levels in Parkinson’s disease treatment76, reduce superoxide dismutase 1 in amyotrophic lateral sclerosis77, and improve clinical symptoms of patients with spinal muscular atrophy78–80. This evidence concerns the gene LRRK2 and Parkinson disease.